EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery

Siqi Wu, Qing Tang, Weifeng Fang, Zhe Sun, Meng Zhang, Ergang Liu, Yang Cao, Yongzhuo Huang

Acta Pharmaceutica Sinica B · 2025-06 · 15 (6) · 3226-3242

DOI: 10.1016/j.apsb.2025.04.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-06. Verfasst von Siqi Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the First Affiliated Hospital and the First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou 510000, Ch…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhongshan Science and Technology Bureau, Natural Science Foundation of Shanghai Municipality, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is aggressive, with high recurrence rates and poor prognosis. Paclitaxel (PTX) remains a key chemotherapeutic agent for TNBC, but its efficacy diminishes due to the emergence of drug resistance, largely driven by cancer stem-like cells (CSCs), vasculogenic mimicry (VM) formation and tumor immunosuppressive microenvironment (TIME). Pyruvate kinase M2 (PKM2) is highly expressed in TNBC, and is a potential target for TNBC treatment. In this study, we developed a biomimetic codelivery system using albumin nanoparticles (termed S/P NP) to co-encapsulate PTX and shikonin (SHK), a natural inhibitor of PKM2. By inhibiting PKM2, SHK suppressed β-Catenin signaling, thereby reversing CSC stemness and preventing VM formation. The S/P NP system exhibited tumor-targeting delivery effect and significantly inhibited TNBC growth and lung metastasis. Mechanistically, the treatment reversed epithelial-mesenchymal transition (EMT) and stem-like properties of TNBC cells, suppressed VM formation, and remodeled the TIME. It reduced immunosuppressive cells (M2 macrophages, MDSCs) while promoting anti-tumor immunity (M1 macrophages, dendritic cells, cytotoxic T cells, and memory T cells). This dual-action strategy holds promise for improving TNBC therapy by targeting CSCs, VM, and the immune microenvironment, and for overcoming PTX resistance and reducing metastasis.

Schlagwörter

Stichwörter der Autor:innen

AlbuminCancer stem-like cellsPaclitaxelPyruvate kinase M2 (PKM2)ShikoninTriple-negative breast cancerTumor microenvironmentVasculogenic mimicry

Autor:innen und Institutionen

  • Department of Oncology, the First Affiliated Hospital and the First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou 510000, China.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
  • State Key Laboratory of Traditional Chinese Medicine Syndrome, Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Guangdong Provincial Hospital of Chinese Medicine, the Second Clinical College of…
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Förderung

  • Zhongshan Science and Technology Bureau
  • Natural Science Foundation of Shanghai Municipality
  • Chinese Academy of Sciences
  • Guangdong Provincial Department of Science and Technology
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Grand Challenges in Global Health
  • National Natural Science Foundation of China National Outstanding Youth Science Fund Project

Zitieren

APA

Wu, S., Tang, Q., Fang, W., Sun, Z., Zhang, M., Liu, E., Cao, Y., & Huang, Y. (2025). Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery. Acta Pharmaceutica Sinica B, 15(6), 3226-3242. https://doi.org/10.1016/j.apsb.2025.04.006

Vancouver

Wu S, Tang Q, Fang W, Sun Z, Zhang M, Liu E, et al. Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery. Acta Pharmaceutica Sinica B. 2025;15(6):3226-3242. doi:10.1016/j.apsb.2025.04.006

BibTeX
@article{Wu2025,
  author = {Wu, Siqi and Tang, Qing and Fang, Weifeng and Sun, Zhe and Zhang, Meng and Liu, Ergang and Cao, Yang and Huang, Yongzhuo},
  title = {Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {3226--3242},
  doi = {10.1016/j.apsb.2025.04.006}
}
Kostenlos starten →